We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+11.71%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$722M
AUM Growth
-$60.1M
Cap. Flow
-$97.7M
Cap. Flow %
-13.52%
Top 10 Hldgs %
77.92%
Holding
44
New
2
Increased
3
Reduced
9
Closed
12

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$19.3M
2
SYRE icon
Spyre Therapeutics
SYRE
+$4M
3
MRUS
Merus
MRUS
+$2.08M
4
NKTR icon
Nektar Therapeutics
NKTR
+$685K
5
ARDX icon
Ardelyx
ARDX
+$96.1K

Top Sells

Rank Stock Value
1
CHRS icon
Coherus Oncology
CHRS
+$27M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$18.4M
3
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$15.6M
4
ACOR
Acorda Therapeutics
ACOR
+$13.2M
5
CDTX
Cidara Therapeutics
CDTX
+$9.24M

Sector Composition

Rank Sector Weight
1 Healthcare 93.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
1
Wave Life Sciences
WVE
$1.11B
$147M 20.31%
7,088,651
– –
ACHN
2
DELISTED
Achillion Pharmaceuticals
ACHN
$93.9M 13%
12,033,220
– –
SIOX
3
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$64.2M 8.89%
625,000
– –
AVXS
4
DELISTED
AveXis, Inc. Common Stock
AVXS
$50.9M 7.05%
1,339,382
-22,200
-2% -$751K
ACRS icon
5
Aclaris Therapeutics
ACRS
$716M
$48.5M 6.72%
2,627,719
– –
NKTR icon
6
Nektar Therapeutics
NKTR
$2.38B
$45.9M 6.35%
214,990
+3,066
+1% +$685K
ASND icon
7
Ascendis Pharma A/S
ASND
$16.6B
$45.3M 6.27%
3,412,857
+1,251,491
+58% +$19.3M
TGTX icon
8
TG Therapeutics
TGTX
$8.25B
$27.5M 3.8%
4,531,714
– –
ARDX icon
9
Ardelyx
ARDX
$1.24B
$20.2M 2.79%
2,312,243
+11,762
+0.5% +$96.1K
ZGNX
10
DELISTED
Zogenix, Inc.
ZGNX
$19.7M 2.73%
2,451,237
– –
VTAE
11
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$17M 2.35%
1,575,000
– –
AIMT
12
DELISTED
Aimmune Therapeutics
AIMT
$14M 1.94%
1,292,940
– –
ARCT icon
13
Arcturus Therapeutics
ARCT
$162M
$13.6M 1.89%
433,273
– –
TARA icon
14
Protara Therapeutics
TARA
$215M
$13.1M 1.81%
40,673
– –
NGNE icon
15
Neurogene
NGNE
$666M
$11.2M 1.55%
84,599
– –
SBBP
16
DELISTED
Strongbridge Biopharma plc.
SBBP
$10.6M 1.47%
2,675,338
-15,364
-0.6% -$72.5K
NTRA icon
17
Natera
NTRA
$36.3B
$9.45M 1.31%
783,520
– –
DMTX
18
DELISTED
Dimension Therapeutics, Inc
DMTX
$9.29M 1.29%
1,548,033
– –
BCRX icon
19
BioCryst Pharmaceuticals
BCRX
$2.43B
$8.49M 1.18%
2,989,795
– –
DRNA
20
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$7.29M 1.01%
2,428,571
– –
SGMO
21
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$6.75M 0.93%
1,165,938
-1,046,098
-47% -$6.67M
AGRX
22
DELISTED
Agile Therapeutics
AGRX
$6.49M 0.9%
427
-105
-20% -$1.44M
TENX icon
23
Tenax Therapeutics
TENX
$397M
$6.12M 0.85%
75
– –
EIGR
24
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$5.78M 0.8%
9,723
– –
ONC
25
BeOne Medicines Ltd
ONC
$34B
$5.07M 0.7%
170,000
– –
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, RA Capital Management held 44 positions worth $722M, down 7.7% from $782M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

RA Capital Management withdrew a net $97.7M in Q2 2016, closing 12 positions and reducing 9 holdings. Its most notable exit was Coherus Oncology, an estimated $27M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 91% a quarter earlier.

Against the trend, RA Capital Management opened a new position in Spyre Therapeutics worth $2.54M.

  • RA Capital Management's largest Q2 2016 buy was Spyre Therapeutics: 20,862 shares worth $2.54M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q2 2016, an estimated $19.3M increase.
  • RA Capital Management's biggest Q2 2016 reduction was Cidara Therapeutics, cutting an estimated $9.24M.
  • RA Capital Management fully exited Coherus Oncology in Q2 2016, selling an estimated $27M.
  • RA Capital Management's ten largest holdings make up 78% of its $722M portfolio in Q2 2016.
  • RA Capital Management opened 2 new positions and closed 12 in Q2 2016.
  • RA Capital Management's portfolio value fell 7.7% quarter-over-quarter to $722M.

Based on RA Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.